DUBLIN, Ohio, Sept. 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced the opening of its newest distribution center in Fort Worth, Texas – a facility solely dedicated to the at-Home Solutions business, a leading medical supplies provider that serves more than 6 million people annually in the United States. In addition, Cardinal Health announced that it will also break ground on a new distribution center dedicated to at-Home Solutions in Sacramento, California, this fiscal year.New Texas facility ...

Core Insights - Dimora Medical has launched the Dimora PHMB Skin and Wound Cleanser to address the challenges of chronic wound care, particularly for aging populations [1][15] - The cleanser effectively tackles biofilms, which complicate over 78% of chronic wounds, by breaking them down and killing 99.99% of bacteria within minutes [1][4][8] Product Features - The main ingredient, Polyhexamethylene Biguanide (PHMB), has demonstrated the ability to remove 99.49% of biofilm within three minutes and 99.99% after seven minutes [5] - The cleanser provides rapid antimicrobial action, killing 99.99% of bacteria in just two minutes for infected wounds and in one minute for non-infected wounds [8][9] - The product maintains its antimicrobial strength over time, achieving a 99.99% reduction in bacteria even after being opened for 28 days [12] Benefits for Caregivers - The cleanser simplifies the wound care process, allowing caregivers to clean and protect wounds quickly without multiple steps [9][15] - It reduces the risk of infection and complications, providing families with greater confidence in managing chronic wounds at home [6][16] - Dimora Medical aims to make home care easier and less stressful for families, positioning itself as a trusted expert in wound care [15][16]

Botswana President Duma Boko has declared a public health emergency and set up a 5 billion pula ($348 million) response plan as a prolonged downturn in diamond sales has caused funds for medical supplies to dry up https://t.co/l7IwNKVuHz ...

Core View - United-Guardian's second-quarter 2025 results indicate a challenging sales environment, particularly in the cosmetic ingredient segment, while showing resilience in pharmaceuticals and medical lubricants [11] Financial Performance - For Q2 2025, net sales were $2.84 million, a decrease of 16.3% from $3.39 million in Q2 2024 [2] - Net income fell 34.5% year-over-year to $626,826, or 14 cents per share, down from $956,225, or 21 cents per share [2] - On a six-month basis, net sales declined 20% to $5.32 million from $6.65 million, and net income slid 36.9% to $1.19 million, or 26 cents per share, from $1.88 million, or 41 cents per share [2] Cost and Expenses - Cost of sales as a percentage of net sales increased to 47% in Q2 2025 from 46% in the previous year [3] - Operating expenses rose 15.1% to $694,050, driven by higher marketing and selling costs [3] - Research and development expenses decreased slightly by 3.4% to $107,868 [3] Sales Performance by Product Category - Pharmaceuticals sales grew 11%, and medical lubricants rose 12% in the first half of 2025 [4] - Cosmetic ingredient sales dropped significantly due to reduced orders from the largest distributor, Ashland Specialty Ingredients, attributed to inventory overstock and softer demand in Asia [4] Management Insights - Management expressed optimism about resolving ASI's inventory issue to restore growth in the cosmetic segment [5] - The company is pursuing a strategic initiative to expand Renacidin's inclusion in drug formularies, which is expected to boost sales in the coming years [5] Factors Influencing Revenue - The year-over-year revenue decline was primarily due to weakness in cosmetic ingredient sales, which outweighed gains in pharmaceuticals and medical lubricants [6] - Higher marketing and selling costs contributed to rising operating expenses, impacting margins alongside the lower sales base [6] Future Outlook - Management anticipates a rebound in cosmetic ingredient sales in the second half of the year, contingent on resolving ASI's inventory overhang [8] - Long-term growth prospects may be supported by the expansion of Renacidin's formulary inclusion, dependent on successful execution of current initiatives [8] Other Developments - No acquisitions, divestitures, or major restructuring activities were disclosed in the quarter [10] - The company's dividend policy remained intact, reflecting continued capital return to shareholders despite profit pressures [10] - Management reaffirmed that its cash position and working capital are sufficient to meet operational needs and support strategic projects over the next 12 months [10]

Core Insights - International Isotopes Inc. reported a revenue increase of 15.3% for Q2 2025 and 13.5% for the first half of 2025 compared to the previous year, driven by sales growth in Nuclear Medicine Standards and Cobalt products [1][2][3] - The company improved its net loss for Q2 2025 to $160,785, a 27% improvement from the previous year, and for the first half of 2025 to $273,479, a 29.4% improvement [1][8] - Non-GAAP EBITDA for Q2 2025 was $1,199, a significant increase from a loss of $84,021 in the same period last year, while the first half of 2025 saw a 157% improvement to $51,569 [1][13] Revenue Breakdown - Revenue from Theranostics Products decreased by 9% to $3,692,233 for the first half of 2025, primarily due to the loss of standing order customers [3] - Revenue from Nuclear Medicine Standards products surged by 99% to $2,340,580 for the first half of 2025, attributed to the resolution of a global shortage of Cobalt-57 isotope [4] - Revenue from Cobalt Products fell by 9% to $750,465 for the first half of 2025, influenced by the timing of sales [5] - Medical Devices segment generated $58,089 in revenue for the first half of 2025, marking its first sales since being established as a reportable segment [6] Financial Performance - Gross profit for Q2 2025 was $2,141,559, a 6.1% increase from the previous year, while total operating expenses rose by 3.6% [7] - The operating loss before other income improved by 25.1% for Q2 2025 compared to the previous year [7] - Adjusted EBITDA for the first half of 2025 was $174,020, a decrease of 51% compared to the previous year [13]

Second Quarter 2025 Continuing Operations Supplemental Earnings Slides August 11, 2025 1 Confidential & Proprietary to Owens & Minor, Inc. The non-GAAP financial measures disclosed by the Company should not be considered substitutes for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth above should be carefully evaluated. Safe Harbor 2 Confidential & Proprietary to O ...

Owens & Minor, Inc. OMI will release earnings results for the second quarter before the opening bell on Monday, Aug. 11. Analysts expect the Glen Allen, Virginia-based company to report quarterly earnings at 28 cents per share, down from 36 cents per share in the year-ago period. Owens & Minor projects to report quarterly revenue at $2.73 billion, compared to $2.67 billion a year earlier, according to data from Benzinga Pro. On June 5, Owens & Minor announced it terminated its Rotech Healthcare acquisition. ...

Core Viewpoint - United-Guardian, Inc. reported a decline in net sales and net income for the second quarter and first half of 2025 compared to the same periods in 2024, although there was a sequential increase from the first quarter of 2025 [1][2]. Financial Performance - Second quarter net sales decreased from $3,390,205 in 2024 to $2,838,225 in 2025, a decline of approximately 16.3% - Net income for the second quarter fell from $956,225 ($0.21 per share) in 2024 to $626,826 ($0.14 per share) in 2025, a decrease of about 34.4% - For the six-month period ended June 30, net sales decreased from $6,645,149 in 2024 to $5,319,352 in 2025, a decline of approximately 20% - Net income for the six-month period decreased from $1,881,667 ($0.41 per share) in 2024 to $1,187,721 ($0.26 per share) in 2025, a decrease of about 37% [1][5][6]. Segment Performance - Sales of pharmaceuticals and medical lubricants increased by 11% and 12%, respectively, in the first half of 2025 compared to the same period in 2024 - The increase in these segments was offset by a decrease in sales of cosmetic ingredients, primarily due to reduced purchases by Ashland Specialty Ingredients (ASI), the largest cosmetic distributor - The decline in ASI's purchases was attributed to softer demand in Asia, leading to an inventory overstock situation [2][3]. Future Outlook - The company is optimistic about improving cosmetic sales in the second half of the year as ASI resolves its overstock situation - A new project is being initiated to include Renacidin, a key pharmaceutical product, in additional drug formularies, which could significantly boost sales in the coming years [2][3].

Earnings Conference Call Q3 FY 2025 August 8, 2025 1 Forward-looking statements Safe Harbor Statement Regarding Forward-Looking Statements This presentation contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations regarding our future results from operations, performance, financial condition, goals, strategies, plans, achievements, and a ...

Core Insights - Embecta Corp. reported strong financial results for Q3 2025, with an increase in revenues and improved profitability metrics despite a challenging geopolitical environment [2][3][8] Financial Highlights - Q3 2025 revenues reached $295.5 million, an increase of 8.4% year-over-year, with U.S. revenues up 11.6% and international revenues up 5.0% [8][10] - Gross profit for Q3 was $197.1 million, with a gross margin of 66.7%, compared to $190.1 million and 69.8% in the prior year [8][20] - Operating income for Q3 was $94.0 million, with an operating margin of 31.8%, significantly higher than $55.9 million and 20.5% in the prior year [8][20] - Net income for Q3 was $45.5 million, or $0.78 per diluted share, compared to $14.7 million and $0.25 in the prior year [8][20] Nine-Month Performance - For the nine months ended June 30, 2025, revenues totaled $816.4 million, a decrease of 2.5% compared to $837.0 million in the prior year [13][20] - Gross profit for the nine-month period was $518.3 million, with a gross margin of 63.5%, down from 67.1% in the prior year [13][20] - Net income for the nine months was $69.0 million, or $1.18 per diluted share, compared to $63.7 million and $1.10 in the prior year [13][20] Strategic Developments - The company successfully implemented its ERP system and operationalized distribution centers in India, concluding a multi-year separation program [3][5] - Embecta is focused on diversifying its product offerings, including contracts with pharmaceutical companies for co-packaging pen needles with generic GLP-1 drugs [5][8] - The company has made significant progress in its brand transition program in the U.S. and Canada, expected to be largely complete by the end of fiscal year 2025 [5][8] Financial Guidance - The updated fiscal year 2025 guidance includes expected reported revenues of $1,078 - $1,085 million, with adjusted earnings per diluted share projected at $2.90 - $2.95 [14][19] - The company anticipates adjusted gross margins of 63.25% - 63.50% and adjusted operating margins of 30.75% - 31.00% for the fiscal year [14][19] Balance Sheet and Liquidity - As of June 30, 2025, the company had approximately $233.6 million in cash and equivalents, with total debt principal outstanding at $1.489 billion [15][21] - The company reduced its debt by approximately $52.4 million during Q3 2025, achieving its fiscal year 2025 debt reduction target with one quarter remaining [8][15]